Results 131 to 140 of about 27,407 (265)

Right Ventricular-Pulmonary Artery Coupling Predicts Early Myocardial Strain Improvement in SGLT2 Inhibitor-Treated HFrEF. [PDF]

J Saudi Heart Assoc
Hammad MA, Elgamal RM, Abouelkhir AM, Elshaer OA, Fahmy MS, Dawoud RN, Biomy R, Salama MK.   +7 more
europepmc   +1 more source

Importance of Hypercortisolism in BP Control, Cardiovascular Risk and in Patients With Difficult‐to‐Control Hypertension: An Overview for Primary Care Physicians

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension remains one of the most prevalent and consequential modifiable cardiovascular risk factors worldwide, affecting approximately 1.28 billion adults globally and nearly half of the United States population. Despite the availability of effective therapies, optimal blood pressure control is achieved in fewer than one in four ...
Matthew A. Cavender
wiley   +1 more source

Clinical Interpretation of Modest Blood Pressure Changes After SGLT2 Inhibitor Initiation. [PDF]

J Clin Hypertens (Greenwich)
Şahin MA, Karaarslan O, Yılmaz MM, Kalçık M.   +3 more
europepmc   +1 more source

How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Endogenous hypercortisolism (EHC) is an underrecognised and clinically significant contributor to hypertension, particularly resistant hypertension. Once viewed as a rare entity, EHC is now understood as a spectrum of cortisol excess associated with adverse cardiometabolic outcomes and target‐organ damage.
Omar Al Dhaybi, Deepak L. Bhatt
wiley   +1 more source

Association Between SGLT2 Inhibitor Use and Hepatocellular Carcinoma Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis. [PDF]

Biomedicines
Hu JH, Chang ML, Huang TJ, Liu NJ, Tang JH.   +4 more
europepmc   +1 more source

SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy. [PDF]

Am Heart J Plus
Sheashaa H, Ibrahim R, Pham HN, Awad K, Scalia IG, Farina JM, Tamarappoo B, Holloway C, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Heterogeneous Kidney Patterns in Diabetic Patients Following SGLT2 Inhibitor Use. [PDF]

J Korean Med Sci
Bae S, Yun D, Kim J, Park S, Kim YC, Kim DK, Oh KH, Joo KW, Kim YS, Han SS.   +9 more
europepmc   +1 more source

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Saichun Zhang, Yunjuan Gu, Yu Cheng, Ying Hu, Bing Li, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Minlu Zhang, Yini Jiang, Qin Du, Lei Kang, Yiming Mu, Weijun Gu, Hongyu Kuang   +14 more
wiley   +1 more source

Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study. [PDF]

Clin Kidney J
Chen YT, Wang CA, Chen JY, Wu VC.
europepmc   +1 more source